We are therefore eager to explore in our model how FOXC2's negative regulation of RIG-I and other IFN pathway genes might contribute to tumor immune evasion and various forms of resistance to clinically relevant cancer immunotherapies. This evidence concerns the gene IFNA1 and neoplasm.